 |  |
Source: Carterra, BusinessWire
Dec.16.2021, Shanghai
Carterra, Inc. the world leader in label-free high throughput antibody screening and characterization, today announced that the company has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer, Inc. a global leader committed to innovating for a healthier world. With the agreement, PerkinElmer will market, sell, and service Carterra’s flagship LSA high-throughput surface plasmon resonance (SPR) platform and software used for accelerating the discovery of therapeutic antibodies.
Dec.16.2021, Shanghai
Carterra, Inc. the world leader in label-free high throughput antibody screening and characterization, today announced that the company has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer, Inc. a global leader committed to innovating for a healthier world. With the agreement, PerkinElmer will market, sell, and service Carterra’s flagship LSA high-throughput surface plasmon resonance (SPR) platform and software used for accelerating the discovery of therapeutic antibodies.
This move will assist Carterra in meeting growing customer demand by leveraging PerkinElmer’s long-standing channel infrastructure in those regions. It will also add additional tools to PerkinElmer’s growing portfolio of science and biologics discovery offerings, which includes its world-leading BioLegend antibody and reagent technologies.
The new agreement builds on the equity investment PerkinElmer made in Carterra last December, which has resulted in several collaborations between the companies involving assay development and software integration projects over the past year.
The new agreement builds on the equity investment PerkinElmer made in Carterra last December, which has resulted in several collaborations between the companies involving assay development and software integration projects over the past year.
Commenting on this latest distribution arrangement, Alan Fletcher, Senior Vice President, Life Science, PerkinElmer, said, “We are delighted to add the distribution of Carterra’s highly innovative LSA technology to help our Asia-Pacific and Oceania customers further streamline and advance their biologic and biotherapeutic discovery and development work.”
“Carterra recognized early on that Asia-Pacific and Oceania would be important markets for our game-changing biologics discovery products and we are at the point where we need additional reach and channel power to help us take our customer delivery there to the next level, ” stated Tim Germann, Chief Commercial Officer at Carterra. “We are excited to collaborate with PerkinElmer to add that extra horsepower in sales, marketing, and service as well as benefit from their deep life science expertise across drug development workflows.”
“Carterra recognized early on that Asia-Pacific and Oceania would be important markets for our game-changing biologics discovery products and we are at the point where we need additional reach and channel power to help us take our customer delivery there to the next level, ” stated Tim Germann, Chief Commercial Officer at Carterra. “We are excited to collaborate with PerkinElmer to add that extra horsepower in sales, marketing, and service as well as benefit from their deep life science expertise across drug development workflows.”
About Carterra, Inc.
Carterra® is privately held and is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, and Munich, Germany. For additional information, please visit www.carterra-bio.com.
Carterra® is privately held and is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, and Munich, Germany. For additional information, please visit www.carterra-bio.com.
RSS Feed